ENOXAPARIN 40mg. IP

An anticoagulant medication commonly used to prevent and treat blood clots in various medical conditions. Low molecular weight heparin for preventing deep venous thrombosis and pulmonary embolism in patients undergoing both orthopedic and general surgical procedures. (S Noble, 1998) A viable option for both prophylaxis and treatment across a broad spectrum of thrombotic conditions. (Meneveau, 2009) A potential alternative to unfractionated heparin is due to a greater bioavailability, lower incidence of heparin-induced thrombocytopenia, and more stable and predictable anticoagulation, enabling fixed dosing without monitoring. (Sinjin Lee, 2007) Reduces ischemic events more effectively than unfractionated heparin in patients treated conservatively for non-ST-segment elevation acute coronary syndrome. (Harvey D White, 2006) Effectively and safely mitigates the risk of venous thromboembolism in patients with acute medical illnesses. (M M Samama, 1999) An efficient and convenient approach for managing unstable angina, offering the potential for cost savings when compared to unfractionated heparin. (S Noble, 1998) An effective agent in reducing both mortality and the incidence of myocardial infarction. (Pranab Das, 2005) The preferred choice over unfractionated heparin for venous thromboembolism prophylaxis in acute ischemic stroke patients. (David G Sherman & Investigators, 2007) Offers a cost-effective treatment option compared to unfractionated heparin for venous thromboembolism prophylaxis in non-surgical patients. (M Asif A Siddiqui, 2005)